Insider · CIK 0001761243
Mark D. Vincent
Files at APTO (Aptose Biosciences Inc.). First filing -, latest -.
In brief
Mark D. Vincent files SEC Form 4 as director at APTO (Aptose Biosciences Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Mark D. Vincent has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 13, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Common Shares | -14 | $1.72 | $24 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -3,333 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -100,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Director Option Grantderivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Director Option Grantderivative | -154,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Stock Options (Right to Buy)derivative | -40,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -10,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -5,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -60,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Feb 5, 2024 | APTO Aptose Biosciences Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +3,333 | $0.00 | $0 | 3,333 | Feb 7, 2024 |
Questions about Mark D. Vincent
Answered from the filings on this page, as of the latest one.
Is Mark D. Vincent buying or selling?
Mark D. Vincent has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Mark D. Vincent's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark D. Vincent has 0.
Where does Mark D. Vincent file Form 4?
Mark D. Vincent has filed Form 4 at APTO (Aptose Biosciences Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.